SP0342 / Dynavax, Sanofi - LARVOL DELTA

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over (clinicaltrials.gov) - P1/2 | N=764 | Active, not recruiting | Sponsor: Dynavax Technologies Corporation | Recruiting ➔ Active, not recruiting

Enrollment closed • Herpes Zoster • Infectious Disease • Varicella Zoster

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over (clinicaltrials.gov) - P1/2 | N=764 | Recruiting | Sponsor: Dynavax Technologies Corporation | N=440 ➔ 764 | Trial completion date: Sep 2026 ➔ Nov 2031 | Trial primary completion date: Sep 2026 ➔ Nov 2027

Enrollment change • Trial completion date • Trial primary completion date • Herpes Zoster • Infectious Disease • Varicella Zoster

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults (clinicaltrials.gov) - P1/2 | N=440 | Recruiting | Sponsor: Dynavax Technologies Corporation

New P1/2 trial • Herpes Zoster • Infectious Disease • Varicella Zoster

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=150 | Completed | Sponsor: Dynavax Technologies Corporation | Recruiting ➔ Completed | Trial completion date: Jan 2023 ➔ Oct 2022 | Trial primary completion date: Jul 2022 ➔ Oct 2022

Trial completion • Trial completion date • Trial primary completion date • Herpes Zoster • Infectious Disease • Varicella Zoster • CD4